MOLINDONE HYDROCHLORIDE
(moe-lin'done)
Moban
Classifications: central nervous system agent; psychotherapeutic; antipsychotic phenothiazine
Prototype: Chlorpromazine
Pregnancy Category: C
|
5 mg, 10 mg, 25 mg, 50 mg, 100 mg tablets; 20 mg/mL liquid
Tranquilizer structurally unrelated but pharmacologically similar to the piperazine phenothiazines; thought to block postsynaptic
dopamine receptors in the brain. Has less sedative but comparable anticholinergic activity and greater incidence of extrapyramidal
adverse effects than chlorpromazine. EEG studies suggest ascending reticular system is chief site of action.
Reportedly lowers convulsive threshold and produces tranquilization without compromising alertness. Antipsychotic effect includes
reduction in bizarre behavior, and control of aggressiveness.
Management of manifestations of psychotic disorders.
Known hypersensitivity to molindone or to phenothiazines; severe CNS depression; comatose states; children <12 y. Safety during
pregnancy (category C) or lactation is not established.
Those harmed by increase in physical activity; prostatic hypertrophy; cardiovascular disease; previously detected cancer of
breast.
Psychotic Disorders
Adult: PO 50–75 mg/d in 3–4 divided doses, may be increased to 100 mg/d in 3–4 d or may be able to decrease to 15–60
mg/d in divided doses (max: 225 mg/d)
|
Oral
- Be certain patient swallows the medication.
- Store medication in tightly capped, light-resistant bottles. Protect from heat and moisture.
CNS: Transient drowsiness, insomnia, extrapyramidal symptoms (dose related), euphoria, neuroleptic malignant syndrome. GI: Dry mouth, constipation, hepatotoxicity. Special Senses: Tinnitus, blurred vision, nasal congestion. Urogenital: Urinary retention. Skin: Mild photosensitivity. CV: Tachycardia. Body as a Whole: Change in weight. Endocrine: SLE-like syndrome, heavy menses, amenorrhea, galactorrhea, gynecomastia, increased libido, premature ejaculation.
Drug: May potentiate CNS depression with cns depressants, alcohol. Herbal: Kava-kava may increase risk and severity of dystonic reactions.
Absorption: Readily absorbed from GI tract. Peak: 1 h. Duration: 24–36 h. Distribution: Distributed into breast milk. Metabolism: Metabolized in liver. Elimination: Excreted in urine and feces. Half-Life: 1.5 h.
Assessment & Drug Effects
- Withhold dose and consult with physician if the following symptoms occur: Tremor, involuntary twitching, exaggerated restlessness,
changes in vision, light-colored stools, sore throat, fever, rash.
- Monitor bowel pattern and urinary output. The depressed patient may not report constipation or urinary retention, both adverse
effects of this medicine.
- Supervise ambulation and other ADL in the older adult or debilitated or patient with impaired vision to prevent injury or
falling because drug increases motor activity.
- Be alert early during treatment to onset of parkinsonism (extrapyramidal) symptoms: Rigidity, immobility, reduction of voluntary
movements, tremors, fine vermicular tongue movements. Withhold dose and report promptly to physician.
Patient & Family Education
- Take drug as prescribed: do not alter dose regimen or stop medication without consulting physician.
- Dizziness during early therapy usually disappears as treatment continues.
- Do not drive or engage in potentially hazardous activities requiring mental or physical coordination until response to drug
is known.
- Avoid alcohol and self-medication with other depressants during therapy. Get physician approval before using any OTC drug.
- Relieve dry mouth by rinsing frequently with warm water, increasing noncaloric fluid intake, sucking hard candy.
- Avoid overexertion (patient with angina) and report increase in frequency of precordial pain.
- Schedule periodic ophthalmic examinations when treatment is long-term.
- Do not breast feed while taking this drug without consulting physician.
1%)
Canadian drug name; 
Prototype drug